As overall healthcare costs continue to rise, biopharma companies are under increasing pressure to demonstrate the economic value of their products and justify prices. This has resulted in competing demands for innovative breakthrough medicines and healthcare cost containment. Ken Kaitin, PhD, Professor and Director, Tufts Center for the Study of Drug Development, joined Pharm Exec to discuss how this conundrum is impacting drug developers. Kaitin is chairing a forum on this issue at DIA’s upcoming 51st Annual Meeting in Washington, DC.
The State of Mining Data Insights in the Life Sciences Industry – 2024
April 30th 2024A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.